🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Welcome, Naimish! Looking forward to having you join our leadership team during this exciting time for CRISPR Therapeutics!

I’m looking forward to speaking on a panel with Jennifer Doudna and Benjamin L. Oakes about the future for CRISPR technology at #AspenIdeasHealth on Friday, June 21 at 11:40am MT / 1:40pm ET. Hope to see some of you there or you can tune in at: bit.ly/4cyAU49@aspeni…

Great to see you Bertha Coombs and thanks for always putting patients first! #aspenideashealth

Very important call to action by ARM! In many cases, a patients natural history data is a better comparator than a control arm in the trial.

Glad there is increasing awareness of Lp(a) as a risk factor and increased testing!

Glad ARM Alliance for Regenerative Medicine (ARM) is championing this cause!

Collab with NHS England and NICE to reach this landmark agreement that recognizes the value that Casgevy can provide to patients, their families and the health care system. businesswire.com/news/home/2024…

Thank you@FierceBiotech, FiercePharma & FierceHealthcare for this recognition and congrats to the full CRISPR Therapeutics team! #CRISPRTX #Fierce50

Incredible to see Jimi summit Kilimanjaro! #SickleCellAwarenessMonth #CRISPR

Clearly, we’re now in the golden age of biology: physiology/medicine Nobel to tiny RNAs; physics Nobel to neural networks; chemistry Nobel to protein structure prediction.

This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.

Dr Peter Marks (head of FDA CBER) makes an apt analogy between #CRISPR and razors in this NPR Rob Stein piece about work we are doing at the Institute for Geographic Information Science UC Berkeley to expand the clinical footprint of gene editing to children with "N=1" gene mutations.

We are pleased to invite Briggs Morrison, M.D., to join our Board of Directors. His extensive experience in the pharmaceutical industry and expertise in clinical development will be invaluable as we continue advancing our platform and pipeline. Learn more: bit.ly/420Fhmf

Agree

Jimi Olaghere interview and how CRISPR can cure patients. We also discuss the other challenges in this space. youtu.be/8ietzVwwqM4?si…

This is a major setback for FDA, improvements in regulatory science, and advancement of innovation for patients! wsj.com/politics/top-v…

U.S. leadership in biotech is a national security, economic, and public health imperative. With the attack on science and universities, instability at FDA, & weakening of the capital markets, we are at grave risk of ceding this leadership to China. This must not happen!

Proud to share our latest business updates and positive top-line results from our Phase 1 clinical trial of CTX310 targeting ANGPTL3. Congratulations to our team and all who contributed to this milestone! CRISPR Therapeutics

Thank you TIME for naming me on the #TIME100HEALTH list! Honored to be included and congrats to all the 2025 honorees. time.com/time100health

We are excited to announce our collaboration with Sirius Tx. This strategic partnership expands our therapeutic toolkit & broadens our cardiovascular portfolio. We look forward to working closely with the Sirius team to advance this exciting asset